Want to see FR:ALMIB full AI Analyst Report?
Amoeba SA (ALMIB) AI Stock Analysis
Amoeba SA
(Paris:ALMIB)
The score is driven primarily by very weak financial performance (revenue collapse, persistent losses and cash burn, and negative equity with rising debt). Technical indicators also point to a bearish trend and weak momentum. Valuation is not clearly attractive because the negative P/E reflects ongoing losses and there is no dividend yield data to offset risk.
Amoeba SA (ALMIB) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 33.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 669.65K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 1.10
- Revenue Growth
- ―
- EPS Growth
- -10.52%
- Country
- France
- Employees
- 23
- Sector
- General
- Sector Strength
- 55
- Industry
- Agricultural Inputs
Amoeba SA Business Overview & Revenue Model
Company Description
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across...
Amoeba SA Financial Statement Overview
Summary
Financial health is very weak: revenue collapsed to zero in 2025, profitability remains deeply negative with persistent net losses, operating cash flow and free cash flow are consistently negative, and the balance sheet shows negative equity alongside rising debt—raising refinancing and funding-risk concerns.
Income Statement
8Very NegativeBalance Sheet
12Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 601.60K | 664.31K | 0 | 0 |
| Gross Profit | -973.03K | -2.57M | -805.57K | -1.71M | -1.01M | -858.95K |
| EBITDA | -7.20M | -7.20M | -5.41M | -13.67M | -4.72M | -4.86M |
| Net Income | -8.30M | -8.30M | -6.59M | -14.30M | -8.02M | -7.82M |
Balance Sheet | ||||||
| Total Assets | 10.13M | 10.13M | 5.65M | 6.29M | 12.39M | 14.50M |
| Cash, Cash Equivalents and Short-Term Investments | 4.72M | 4.72M | 458.94K | 519.33K | 5.53M | 7.28M |
| Total Debt | 12.24M | 12.24M | 12.07M | 4.92M | 2.36M | 12.50M |
| Total Liabilities | 15.49M | 15.49M | 16.06M | 10.23M | 4.23M | 14.30M |
| Stockholders Equity | -5.36M | -5.36M | -10.41M | -3.94M | 8.16M | 213.68K |
Cash Flow | ||||||
| Free Cash Flow | -7.42M | -7.42M | -4.78M | -12.59M | -5.71M | -6.05M |
| Operating Cash Flow | -6.13M | -6.13M | -4.22M | -6.50M | -5.40M | -5.90M |
| Investing Cash Flow | -1.30M | -1.30M | -2.01M | -2.81M | -212.13K | -140.65K |
| Financing Cash Flow | 11.69M | 11.69M | 6.16M | 4.30M | 3.87M | 4.98M |
Amoeba SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMIB, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.45, and below the 200-day MA of 0.75, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 18.63 is Positive, neither overbought nor oversold. The STOCH value of 9.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMIB.
Amoeba SA Peers Comparison
Overall Rating
FR:COH73Outperform
FR:ALATA50Neutral- FR:ALMIB41Neutral
FR:BIG38Underperform
FR:ALCLA32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:COH | 73Outperform | EUR 46.51M | 15.43 | 12.54% | 0.98% | 8.58% | -18.77% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:ALATA | 50Neutral | EUR 65.77M | -7.55 | -101.20% | ― | 66.67% | 74.66% |
| FR:ALMIB | 41Neutral | EUR 33.06M | -1.83 | 120.24% | ― | ― | -10.52% |
| FR:BIG | 38Underperform | EUR 1.19M | -0.00 | -403.52% | ― | -1.22% | -101445.24% |
| FR:ALCLA | 32Underperform | EUR 28.31M | 6.18 | 10.38% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALMIB | Amoeba SA | 0.26 | -0.75 | -74.65% | |
| FR:ALJXR | Archos | 0.26 | 0.07 | 33.68% | |
| FR:ALATA | Atari SA | 15.47 | -12.03 | -43.75% | |
| FR:ALCLA | Claranova SA | 0.50 | -1.15 | -69.84% | |
| FR:BIG | Bigben Interactive | 0.07 | -1.00 | -93.90% | |
| FR:COH | Coheris | 8.18 | -6.33 | -43.61% |
Amoeba SA Corporate Events
Amoéba Confirms 2026 Half-Year Results as It Scales Amoeba-Based Greentech
Amoéba SA has published and filed its half-year financial report as of June 30, 2026 with the French market regulator AMF, confirming figures previously disclosed in September. The financial statements were approved by the board and received a l...
Amoéba Secures €17.6 Million in Equity and Cuts Debt as It Prepares for Biocontrol Ramp-Up
Amoéba has completed a capital increase with preferential subscription rights, issuing over 32 million new shares with attached warrants and raising gross proceeds of €9.7 million at a subscription rate above 104%. Combined with a €7...
Amoéba Details Free Warrant Terms in Capital Increase as Greentech Expansion Advances
Amoéba is reinforcing its presence in the biocontrol and cosmetics sectors by leveraging its patented Willaertia amoeba technology, which has obtained key approvals for its AXPERA plant protection product in the United States and France, and is...
Amoéba launches €10 million capital increase to fund biocontrol rollout and cosmetics monetization
Amoéba has launched a roughly €10 million capital increase with preferential subscription rights preserved for existing shareholders to fund the commercial rollout of its biocontrol activity and prepare the monetization of its WillaTM cosm...
Amoéba Secures 75% of €10 Million Capital Increase Ahead of Investor Webinar
Amoéba SA is launching a capital increase with preferential subscription rights for existing shareholders, targeting around €10 million to support its strategic development. The offer is structured via ABSAs priced at €0.30 per unit,...
Amoéba launches €10m capital increase to fund biocontrol push and cosmetics monetization
Amoéba has launched a roughly €10 million capital increase via shares with subscription warrants, preserving preferential rights for existing shareholders, to fund the commercial rollout of its biocontrol products over the next year and br...
Amoéba Raises €7.9 Million and Launches Rights Issue to Fund Greentech Expansion
Amoéba SA has completed a €7.9 million share capital increase via a private placement with qualified investors at €0.416 per share, bringing its share count to 96,884,338 and slightly diluting existing holdings while increasing Nice...
Amoéba launches dual equity raise to fund growth and bridge to profitability
Amoéba SA has launched a two‑step equity fundraising totaling more than €15 million, combining an accelerated private placement aimed at qualified investors with a subsequent capital increase open to all shareholders via preferential...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026